New drug combo aims to shrink tough breast cancer before surgery

NCT ID NCT07351487

Recruiting now Disease control Sponsor: First Affiliated Hospital of Zhejiang University Source: ClinicalTrials.gov ↗

Summary

This study is testing a treatment plan for triple-negative breast cancer before surgery. The plan combines standard chemotherapy with two immunotherapy drugs, sintilimab and bevacizumab. The main goal is to see if this combination can completely eliminate the cancer in the breast tissue, which is measured after surgery. Researchers will also track side effects and how long patients remain cancer-free.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for TNBC - TRIPLE-NEGATIVE BREAST CANCER are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••
Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

The First Affiliated Hospital of Anhui Medical University
RECRUITING

Hefei, China

Contact
Zhongshan Hospital, Fudan University
RECRUITING

Shanghai, China

Contact

Conditions

Explore the condition pages connected to this study.

TNBC - TRIPLE-NEGATIVE BREAST CANCER